Niraparib Plus Abiraterone Significantly Improves rPFS in HRR‑Deficient mCSPC: AMPLITUDE Phase 3 Results
The AMPLITUDE phase 3 trial shows adding niraparib to abiraterone‑prednisone improves radiographic progression‑free survival in HRR‑deficient metastatic castration‑sensitive prostate cancer, with greater benefit in BRCA‑altered disease but increased toxicity.